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Abstract 
Opioid addiction is a spiralling global epidemic associated with intense drug craving and the 
compulsive use of opiate drugs such as heroin, oxycodone, oxymorphone amongst others. 
Buprenorphine (BUP), commercially available as Subutex, is a partial opioid agonist that is 
used to treat opioid addiction and pain.  It is associated with minimal risks of overdose and can 
be used outside of clinical care, making it the safest and most preferred choice of drug in the 
treatment of opioid addiction, over methadone and naltrexone.  Literature suggests that opioids 
carry out their effects by altering the neurotransmitter systems of the brain viz. dopamine, 
norepinephrine, serotonin, glutamate and gamma-aminobutyric acid. Therefore, an ideal 
treatment drug should be able to counter these neurotransmitter changes in the brain. There is 
currently a lack of information on the pharmacodynamic effects of BUP in the brain, more 
specifically on how the drug affects brain neurotransmitter levels and its effect on the 
transcription factors Brain-derived neurotrophic factor (BDNF) and Cyclic AMP Response 
Element-Binding Protein (CREB). 
This study evaluates the pharmacokinetics of BUP, its effect on neurotransmitter levels and the 
expression of BDNF and CREB at various time points following a single dose. Sprague-
Dawley rats received 36 µL of 0.3 mg/mL of BUP via intranasal administration. Following 
dosing, animals were euthanised and brain tissues were collected at different time points. A 
rapid and sensitive liquid chromatograph-mass spectrometry (LC-MS method was developed 
for the quantification of BUP and neurotransmitters (dopamine, serotonin, glutamate, 
norepinephrine and gamma-aminobutyric acid) in brain tissue and the expression of CREB and 
BDNF was determined using qPCR. This thesis is divided into three chapters. Chapter 1 
contains a thorough background on BUP, opioid addiction and the role of neurotransmitters, 
BDNF and CREB. It also explains the principles of the quantification techniques used in this 
study i.e LC-MS and qPCR. Chapter 2 is a manuscript that was submitted to Addiction 
Biology titled “Functional and molecular changes associated with intranasal buprenorphine 
administration in a healthy rodent model”. Lastly, Chapter 3 provides a general conclusion 
and future recommendations for the study.   
The results in this present study indicate that BUP leads to significant changes in 
neurotransmitters, CREB and BDNF over time. Providing a better understanding of the 
mechanism of action of the drug, which could possibly improve the treatment of opioid 
addiction. 
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Opioid addiction is a severe global health concern, according to CDC 46 802 deaths were 
recorded in the US alone due to opioid overdose, in 2018. Opioids are the main treatment for 
severe acute, perioperative, chronic pain in cancer and lower-back pain. 1,2 Their application 
has also been encouraged in the treatment of chronic diarrhoea, for example with Loperamide. 
3,4 Using opioids to treat pain has the potential to lead to opioid addiction over time, meaning 
pain and opioid addiction are not mutually exclusive. 5 Society has the misconception of heroin 
being the only addictive opioid, but the misuse of prescription opioid medications, such as 
oxycodone, morphine or codeine does result in the number of people being dependent on 
opioids increasing dramatically and ultimately being a significant public health concern. 6 
Opioids are described as chemicals that bind to mu (µ), delta (δ) and kappa (κ) receptors, which 
form members of the large family of G protein-coupled receptors (GPCRs). 7  
 To help individuals struggling with opioid addiction, medication-assisted treatment (MAT) is 
often implemented; which comprises of pharmaceutical intervention and psychotherapy in the 
form of counselling and support from family and friends. 8 Psychosocial therapy involves 
patients controlling their urges to use drugs, the emotional strife and remain abstinent. 9 
Buprenorphine (BUP) is one of four pharmaceutical agents used to treat opioid addiction, the 
others being methadone, naltrexone and naloxone. 10-12   Methadone is highly potent as a full 
opioid agonist, however it also comes with the increased  likeliness of overdose. 13  Although 
methadone can be used by pregnant women, less treatment is required for Neonatal Abstinence 
Syndrome (NAS) for babies born of mothers treated with buprenorphine than methadone. 14 
Naltrexone on the other hand requires a complete detox prior to treatment and cannot be taken 
by pregnant women or breastfeeding mothers. 15,16 Naloxone is an opioid antagonist that is 
recommended for patients with high overdose risk, to combat opioid overdose mortality.17,18 
BUP however has been found to be the safest and most preferred option in the treatment of 
opioid addiction as it carries lower risks of overdose and can be used without any supervision. 
19,20 The above-mentioned disadvantages/limitations of methadone and naltrexone have, 
together with the lack of information surrounding its pharmacodynamic effects have led to 
BUP being selected as the drug of interest in this study. BUP, just like any other opioid carries 
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out its function by altering certain neurotransmitter pathways that control mood, appetite and 
reward.21 
This highlights the importance of the quantification of neurotransmitters in the evaluation of 
the action of neuroactive drugs, in order to provide a better understanding of their 
pharmacodynamic effects and which diseases they would be most effective in treating. 21,22 
Opioids are known to interact with  three main neurotransmitter systems; the dopaminergic, 
glutamatergic and noradrenergic pathways 23   with literature also suggesting that GABA and 
serotonin being altered in during addiction. To date, there is no information regarding 
neurotransmitter level changes with time associated with BUP administration.  
1.2 Opioids 
Opioids are a group of substances derived from a the naturally occurring plant-based 
compound, opium .24 Opioids include natural, semi-synthetic and synthetic chemicals which 
confer anti-nociception effects by acting at the opioid receptors in the central nervous system 
(Table 1.1). They are characterized by their ability to bind to the mu-, kappa- and delta-opioid 
receptors, followed by a subsequent alteration in neural signal transmission. 25 Opioids include 
both prescription drugs and illicit-narcotic agents. They can be divided into two classes; 
endogenous opioids, referring to those opioids that are produced by the body and exogeneous 
opioids that are introduced into the body. 2 Within the exogenous group are the naturally 
occurring opioids, semi-synthetic opioids and lastly fully synthetic. 26 
 
Table 1.1: Examples of different classes and subclasses of opioids 
Classes of Opioids Subclass Examples 




 Naturally occurring morphine, codeine, thebaine 
and noscapine 
 
Exogeneous opioids Semi-synthetic  diamorphine, oxymorphone, 
oxycodone, buprenorphine 
 
 Fully synthetic  methadone and pethidine 
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1.3 Opioid Addiction 
Opioid misuse is a spiralling global epidemic that is associated with high rates of mortality and 
morbidity due to fatal drug overdose, elevated health care costs, social harms, public disorder 
and crime. 27,28 This disorder affects both users of illicit drugs and patients abusing prescription 
opioids, along with their families. Approximately, 12-21 million people use opioids worldwide, 
with an annual death toll of 69 000 and the number of non-fatal overdoses many times higher. 
29 There has also been a prominent rise in incidences where infectious diseases   such as 
Hepatitis C and HIV are a consequence of promiscuous behaviour that occurs as a result of 
drug intoxication and the intravenous use of illicit opioids. 30,31 Dependence and addiction are 
used interchangeably, but there is a reasonable difference in these terms, which is why the 
American Academy of Pain Medicine, along with the American Pain Society and the American 
Society of Addiction Medicine developed a consensus document with their definitions as: 
“Addiction is a primary, chronic, neurobiological disease with genetic, psychosocial, and 
environmental factors influencing its development and manifestations. It is characterized by 
behaviours that include 1 or more of the following: impaired control over drug use, compulsive 
use, continued use despite harm, and craving”. Whereas “Physical dependence is a state of 
adaptation that is manifested by a drug class-specific withdrawal syndrome that can be 
produced by abrupt cessation of a drug, a rapid dose reduction decreasing blood level of the 
drug, and/or administration of an antagonist”. 32 Addiction is more intense as the cravings 
experienced lead to relapse or months or years after the patient is no longer opioid dependent. 
33 
Interestingly, certain individuals’ have a genetic disposition to developing  opioid addiction, 
even when the medications are prescribed appropriately and taken as directed. 34 Opioid 
addiction becomes a chronic relapsing disease as opioids change the chemistry of the brain and 
lead to drug tolerance, meaning that the dose needs to be increased periodically to achieve the 
same effect. 35,36 On a molecular level, tolerance is thought to be a consequence of 
desensitization of the mu-opioid receptors leading to alterations in opioid receptor signalling. 
32 Opioids are most addictive when you take them using routes of administration different from 
what was prescribed, such as crushing a pill so that it can be snorted or injected. 37 This alters 
the pharmacokinetic properties of the drug and causes rapid distribution of the opioid, resulting 
in an accidental overdose where there is respiratory depression or cessation, ultimately leading 
to unconsciousness or death if the overdose is not treated immediately. 38 Opioid misuse is 
associated with adverse effects such as severe respiratory depression, causing constriction of 
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the pupils (often referred to as pinpoint pupils), a decrease in oxygen saturation, loss in appetite, 
nausea, sedation, euphoria and constipation. 39,40 Upon discontinuation of opioid drugs, a 
severe withdrawal syndrome is experienced and is characterised by stomach cramps, diarrhea, 
rhinorrea, sweating, elevated heart rate, increased blood pressure and negative neurological 
effects including dysphoria, anxiety and depression. 41,42 There are currently three approved 
drugs that are used in the treatment of opioid addiction; methadone, naltrexone and BUP The 
focus of this study was to better understand the role of BUP in the treatment of opioid addiction 
by investigating the changes in neurotransmitter (NT) levels and the expression of transcription 
factors associated with its use. 
1.4 Treatment of Opioid Addiction Using Buprenorphine (BUP) 
Buprenorphine (BUP) is often  prescribed in the treatment of opioid addiction due to its 
improved safety profile compared to other available treatment drugs, however its primary 
pharmaceutical indication is for the treatment of pain. 43 BUP is a semi-synthetic opioid derived 
from thebaine, a naturally occurring alkaloid of the opium poppy, Papaver somniferum. 44 The 
chemical structure of the BUP (Figure 1.1), is analogous to morphine, which is also a widely 
used opioid analgesic drug. 44 The distinguishing factor between the two is the presence of a 
cyclopropyl methyl on BUP and the C-7 side chain containing a t-butyl group which makes the 
drug highly lipophilic and enables easy diffusion across the blood brain barrier (BBB). 44,45 In 
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time, upon daily intake. 53 In addition, sublingual BUP is misused through parenteral 
administration and diversion to the illegal market. 54 This has led to the development of a 
buprenorphine/naloxone (4:1) formulation to prevent misuse, this is due to naloxone’s  MOR 
antagonistic properties. 46,55 BUP is well absorbed by patients with even significant renal 
dysfunction without any dose adjustment required. 32,56 BUP carries out its effects by altering 
neurotransmitters such as norepinephrine, serotonin, dopamine, glutamate and γ-aminobutyric 
acid (GABA). 
1.5 The Role of Neurotransmitters in Opioid Addiction 
The nervous system functions through the communication of cells using chemical messengers, 
known as neurotransmitters, that transmit signals across synapses from presynaptic cells to 
activate receptors on postsynaptic cells. 57,58 This interaction of cells is responsible for the 
modulation of motor movements, personality and behaviour of individuals. Therefore, any 
disturbances in this finely balanced system produces behavioural disorders and can promote 
certain neurobiological and psychiatric conditions. 21,59  According to their chemical structures, 
neurotransmitters (NTs) can be classified (Table 1.2) as amino acid transmitters including 
glycine, glutamate and gamma-aminobutyric acid (GABA); as monoamines/biogenic amine 
transmitters including dopamine, serotonin, epinephrine, norepinephrine; and lastly as 
neuropeptides including enkephalin, endorphin and substance P. 60   
Table 1.2: Different classes of neurotransmitters and their examples. 
Class of neurotransmitters Examples 
Amino acid transmitters Glycine, glutamate, GABA 
Monoamines/ biogenic amine transmitters Dopamine, serotonin, norepinephrine 











Opiate drugs result in a feeling of pleasure through the indirect release of dopamine,  the 
principal central nervous system neurotransmitter that is responsible for behaviour, control of 
movement, cardiovascular function, endocrine regulation and strongly associated with 
addiction. 59,61 The mesocorticolimbic dopamine (DA) system is known to be highly active in 
patients who suffer from drug addiction and is the major site of action for addictive drugs. 62  
The system originates from the ventral tegmental area (VTA) with  projections to the nucleus 
accumbens (NAc) and prefrontal cortex (PFC). 63,64 In the VTA, opiate drugs principally target 
GABAergic interneurons for two possible reasons: firstly, MORs are expressed on GABAergic 
and not on DA neurons or secondly, GABA neurons are more sensitive to the drug than DA 
neurons. 62 Upon binding, GABAergic neurons are inhibited (Figure 1.2), which leads to an 
indirect increase in activity of DA neurons, thus inducing the release of DA in NAc and PFC. 
62,65 
Withdrawal symptoms in long term opioid users involves the locus coeruleus (LC) region of 
the brain (Figure 1.2), where neurons produce norepinephrine (NE). 33 This neurotransmitter 
regulates alertness, breathing, blood pressure and mood. 66 Opioid binding to MORs in the LC 
neurons supresses the release of NE, resulting in drowsiness, slowed respiration and lower 
blood pressure. 33 Repeated exposure to opioids, leads to heightened activity of LC neurons; 
when opioids are no longer present in the system to supress the enhanced neuronal activity and 
the release of excessive amounts of NE. 67 This excessive release of NE is characterised by the 
physical symptoms of opioid withdrawal which include jitters, anxiety, muscle cramps and 
diarrhea. 67 
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Figure 1. 2: The Mesocorticolimbic Dopamine System and the Locus Coeruleus (LC) as 
a target of opioid Drugs. Opioid drugs act indirectly via pre- and post-synaptic inhibition 
of GABAergic interneurons to activate the release of dopamine by DA neurons. The LC 
neurons release norepinephrine when opioids bind to the MORs (prepared by author). 
 
Glutamate has been identified as the major excitatory neurotransmitter in the brain and plays 
an important role in opioid addiction. 68 In the reward and withdrawal aspects of consuming 
opiates, opioid memories are formed and maintained by glutmate.69,70 Glutamate receptors are 
critically involved in the process of reward and withdrawal. 71 There are two categories of 
glutamate receptors, the ionotropic glutamate receptors (iGluRs) and metabotropic glutamate 
receptors (mGluRs). 72 Within the iGluRs, a subtype known as the N-methyl-D-aspartic acid 
(NMDA) receptor stands out as most commonly implicated in the rewarding effects of opiates. 
72 It has been suspected that glutamate may be involved in the processes of opioid addiction 
through its interaction with other neurotransmitters or neuropeptides such as, dopamine, 
GABA and substance P in the mesocorticolimbic dopaminergic regions. 68 
 
Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter that affects mood 
and cognition. 73,74 The neurotransmission of 5-HT plays a part in developing dependence and 
the expression of withdrawal from morphine. In addition, chronic morphine treatment is 
associated with an increase in expression of the 5-HT2C receptor protein in the VTA, LC and 
NAc. 74,75 With the gathered evidence showing that neurotransmitters play a critical role in 

10 | P a g e  
 
endogenous BDNF is critical for the normal development and function of 5-HT neurons, there 
is no information on how endogenous BDNF influences neurotransmission of 5-HT following 
opioid intake.84  
CREB is a transcription factor that is involved in neuronal survival, learning, long-term 
memory and drug dependence. 85,86 Research shows that acute administration of opiates inhibits 
the  cAMP signalling pathway, thus decreasing locus coeruleus (LC) neuronal firing. 87 
Contrary to acute, chronic exposure to opiates upregulates the  cAMP system that leads to 
tolerance, dependence and drug-seeking behaviour. 77,88 Brain regions that have been observed 
to take part in this upregulation are the LC and NAc which have been shown an increase in the 
expression and phosphorylation of CREB. 86 Phosphorylated CREB activates transcription by 
binding to the CRE promotor region of target genes as a dimer and modulates their expression. 
23,89 CREB signalling also regulates the expression of BDNF, this CREB-BDNF signalling is 
said to be critical in cell survival, synaptic structure and synaptic plasticity. 90,91 
To date there are no reports demonstrating the effect of BUP administration on the expression 
of CREB and BDNF and their potential role in the management of opioid addiction. 
1.7 Liquid Chromatography- Mass Spectrometry (LC-MS) 
Liquid Chromatography -Mass Spectrometry (LC-MS) is a powerful analytical technique used 
for the quantitative bioanalysis of pharmaceuticals and other biological analytes of interest. 92 
This  method is gaining high popularity in  neuroscience research over other analytical methods 
such as enzyme linked immunosorbent immunoassay (ELISA), radioimmunoassay (RIA), gas 
chromatography, capillary electrophoresis as these methods are time consuming and costly, 
requiring pre and post-column derivatisation and time-consuming sample preparations with 
long chromatographic separations. 93,94 LC-MS has a high sensitivity and specificity, with a 
high applicability for complex biological matrices such as body fluids and tissues. 93,95 
A typical LC-MS system functions by combining the separating power of high-performance 
liquid chromatography (HPLC), with the detection power of mass spectrometry. Figure 1.4 
depicts the basic components of an LC-MS system, the first part being the liquid 
chromatography component, this is where a complex sample is injected to the column and 
separated based on the affinity of its individual components to the stationary phase. Secondly, 
the mass spectrometer where ionisation of compounds and detection occurs. 
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Figure 1. 4: Schematic representation of a Liquid Chromatography Mass Spectrometric 
(LC-MS) system (prepared by author). 
 
 
1.7.1 Liquid - Chromatography 
a) Solvent Reservoir 
The solvent reservoir contains the mobile phase used to carry the sample through the system. 
96 The solvents used depend on the different types of HPLC. Normal-phase HPLC, uses a 
nonpolar solvent and reverse-phase HPLC uses a mixture of water and a polar organic solvent. 
97 To improve the chromatographic peak shape and signal of analyte, the mobile phase is spiked 
with an acid, most commonly acetic acid and formic acid, which provide a source of protons 
in reverse phase or act as ionising agents in the source of the mass spectrometer. 98 The solvent 
is propelled through the system by the pump 
b) High Pressure – Pump 
Pumps are regarded as the heart of the HPLC as they generate the high pressures required and 
provide the gradient to drive sample separation. Depending on the application; piston, electro-
osmotic, diaphragm, reciprocating and syringe pumps are used. To entirely push samples, at a 
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uniform flow rate, through the system, the pressure of pumps typically range between 50-400 
bar. 99 
c) Injector 
An injector or autosampler, allows for precise sample volume introduction onto the mobile 
phase flow entering the column, without interfering with the set flow rate and pressure of the 
HPLC system. It is mandatory that the sample is introduced without and air bubbles that will 
disturb the pressure of the system. The most used injector is the rheodyne injector, with others 
being the septum and stop flow injector. Regardless of the type of injector, high switching 
precision, low dead-volume and minimal flow disturbance are key characteristics for obtaining 
in the reduction of band broadening and increasing resolution. 99 
d) Column 
This is the first part of the system where separation occurs. The compounds or analytes in a 
sample are eluted in accordance to the degree at which they interact with the column stationary 
phase. A combination of a polar stationary phase and a non-polar mobile phase is referred to 
as a normal phase column. The polar silica packed around the column retains polar molecules, 
whereas non-polar molecules are eluted first with the mobile phase. 100 In a reversed phase 
column, the stationary phase is packed with modified silica to make it non-polar (silica-C18 
molecule) and is compatible polar mobile phases. 101,102 This type of column can be applied to 
a wider range of organic molecules and uses aqueous based mobile phases, making it of high 
importance in biological research. 100,103-105 Once the sample has been separated accordingly it 
moves towards the mass spectrometer for detection. 
 
1.7.2 Mass Spectrometry 
e) Ionisation Source 
The ionisation source is a compartment of the instrument where charged molecular species are 
produced. 106  Electrospray ionisation (ESI) is the most commonly used ionisation technique 
and has routinely been used  in the study of biologically important analytes . 107 This is regarded 
as a soft ionisation technique, meaning that minimum internal energy is transmitted to the 
analytes during the ionisation process. 106  The sample is preferably soluble in a polar solvent 
and is introduced at atmospheric pressure through a needle at a potential difference. 108 The 
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applied voltage, usually in the range 3-4 kV, is dependent on the inner diameter of the needle 
and the solvents used. 106 This results in the formation of highly charged droplets, that are 
vaporised with the aid of a warm neutral gas such as nitrogen (known as the nebulizer gas). As 
the droplets progress through the ion source they become smaller and the coulombic forces 
between them increase and ultimately exceed the surface tension of the solvent generating ions. 
108,109 The ions are then released to the gas phase and make their way to the mass analyser. 110 
Unlike other ionisation methods, ESI can analyse non-volatile organic and inorganic 
compounds, with masses ranging from very low to extraordinarily high. 107,111  
f) Mass analyser 
This part of the mass spectrometer is responsible for sensitivity through  sorting and separating 
ions according to their mass-to-charge ratio (m/z). 112 The most commonly used types of mass 
analysers are the quadrupole and time of flight (TOF). The quadrupole analyser acts as a mass 
selective filter, consisting of four hyperbolic rods that are parallel to each other, when a voltage 
is applied, this allows the transmission of a narrow band of m/z values along the axis of the 
rods. Varying the voltage with time allows the transmission of  a certain range of m/z values, 
resulting in a spectrum. 113 Quadrupole mass analysers are of great interest since they are 
relatively of low cost, tolerant to high pressures and are useful for the analysis of large 
biomolecules. 109,113 
 
The TOF mass analyser is known as the simplest and operates by accelerating ions at a fixed 
potential (1-20 kV) through a flight tube to the detector. 110 These ions travel a fixed distance 
of between 0.5-2.0 metres before colliding with the detector, depending on their m/z values. 
Higher m/z value ions have lower velocities in comparison to the lower m/z ions, meaning they 
are last to reach the detector. 110  Through measuring the time it taken to reach the detector after 
the ion is formed, the m/z of the ion can be determined. 110 This particular mass analyser has 
high mass accuracy, that enables the determination of molecular formulas for small molecules. 
114 To improve the analyses of ions, tandem mass spectrometers that combine different mass 
analysers have been developed. Combining the quadrupole mass analyser with the TOF mass 
analyser produces a hybrid quadrupole time-of-flight (QTOF) mass analyser. 114  The QTOF 
has led to higher resolution mass spectrometers, 106 while triple quadrupole (QQQ) mass 
spectrometers allow for greater mass sensitivity. 
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g) Detector 
When ions collide with the detector, the collision is recorded in the form of a mass spectrum, 
which is a plot of the relative abundance of ions versus their mass-to-charge ratio (m/z), which 
is the typical output (Figure 1.4). 115 There are two detectors that are normally used in mass 
spectrometry, viz. the electron multiplier (EM) and the Faraday cup. The EM is made up of a 
series of aluminium oxide dynodes with increasing potential. When ions strike the first dynode 
surface, electrons are emitted, which then move to the next dynode held at a higher potential 
and as a result more secondary electrons are generated. 56,116 Amplification is accomplished as 
secondary electrons are produced from dynode to dynode, this better known as a “cascading 
effect”. 109 
The Faraday cup is a typical electrical detector, where a beam of positive ions impinging on 
the collector are neutralised by electrons. Ions strike the dynode surface, made up of BeO, GaP 
or CsSb, which causes the ejection of secondary electrons. 56 This detector can tolerate high 
pressures, has high accuracy, constant sensitivity and low electrical noise. Nevertheless, when 
compared to EM this detector is less sensitive as there is very little amplification of signal. 109 
1.8 Polymerase Chain Reaction (PCR) 
The basic purpose of polymerase chain reaction (PCR) is to rapidly make numerous copies of 
a specific region of DNA or RNA. It is usually used to amplify and clone genes for gene 
expression studies, paternity testing, diagnosis of genetic diseases, forensics and detection of 
bacteria and viruses. 117-119 There are three principal steps in a PCR reaction; denaturation, 
primer annealing and extension. 120 These are often repeated over 25-40 cycles employing an 
automated thermal cycler. 121 The first step, denaturation occurs at 94-95˚C where the double-
stranded DNA is separated into a single-stranded DNA, which serve as a template. 120 The 
second step, primer annealing, occurs at a temperature optimised for the specific primers 
according to their composition and length. 120 Primers, short oligonucleotides are 
complementary to the ends of the DNA sequence to be amplified, they attach to the template 
DNA and enable the polymerase enzyme to attach and copy the template. 121 The last step, 
extension, is where nucleic acid bases are added onto the template strand at72˚C. After each 
subsequent PCR cycle there is an exponential increase in the number of gene copies 120,121 
Agarose gel electrophoresis is usually used to confirm the desired product of PCR. 121 Real-
time quantitative reverse transcription PCR (RT-qPCR) is a sensitive, rapid and accurate 
technique that has become a method of choice in gene expression studies, which follows the 
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same principle as PCR. 117,122 The starting point is the RNA, which is used as a template to 
synthesise complementary DNA (cDNA), which is then used as a template for the quantitative 
PCR (qPCR) reaction. 117  When performing qPCR, a fluorescent dye-labelled probe or 
fluorescent DNA-intercalating dye is used as an indirect measure of the amount of nucleic acid 
present during each amplification cycle. 123 A standard curve can be achieved through 
measuring the PCR cycle for samples at which fluorescence reaches a certain threshold, known 
as the threshold cycle value (CT). 
123 qPCR allows for the determination of the expression of a 
particular gene when compared to a housekeeping gene. 
1.9 Aim and objectives 
Aim: To investigate the functional and molecular changes associated with BUP administration 
in a healthy rodent model. 
Objectives: 
I. To determine the pharmacokinetic properties of BUP in the rodent brain following the 
intranasal administration of a 0.3 mg/mL dose.  
II. To monitor brain neurotransmitter changes at different time points post-BUP 
administration using LC-MS. 
III. To determine changes in the expressions of CREB and BDNF genes at different time 
points following BUP administration, using qPCR. 
 
1.10 Outline of thesis 
Chapter 1 provides a thorough background on BUP, opioid addiction and how it effects 
neurotransmitters, BDNF and CREB. In addition, explains the principles of the quantification 
techniques used in this study; LC-MS and qPCR.  
Chapter 2 is a manuscript which was submitted to Addiction Biology titled “Functional and 
molecular changes associated with intranasal buprenorphine administration in a healthy rodent 
model”.  
Chapter 3 provides a general conclusion and future recommendations for the study. 
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ABSTRACT 
Buprenorphine is an opioid drug used in the management of pain and the treatment opioid 
addiction. Like other opioids, it is believed that it achieves these effects by altering functional 
neurotransmitter (NT) pathways and the expression of important transcription factors in the 
brain, however there is a lack of scientific evidence to support these theories. This study 
investigated the pharmacodynamic effects of BUP administration by assessing 
neurotransmitter and molecular changes in the healthy rodent brain.  Sprague-Dawley rats (150 
– 200g) were intranasally administered buprenorphine (36 µL of 0.3 mg/mL) and sacrificed at 
different time points: 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h post drug administration. LC-MS was 
used to quantify BUP and neurotransmitters (GABA, GLUT, DA, NE and 5-HT) in the brain; 
while CREB and BDNF gene expression was determined using qPCR. Results showed that 
BUP reached a Cmax of 1.21 ± 0.0523 ng/mL after 2 h, with all neurotransmitters showing an 
increase in their concentration over time, with GABA, GLUT and NE reaching their maximum 
concentration after 8 h. DA and 5-HT reached their maximum concentrations at 1 h and 24 h, 
respectively post drug administration. Treatment with BUP resulted in significant upregulation 
in BDNF expression throughout the treatment period while CREB showed patterns of 
significant upregulation at 2 and 8 h, and downregulation at 1 and 6 h. This study contributes 
to the understanding of the pharmacodynamic effects of BUP in opioid addiction by proving 
that the drug significantly influences NT pathways that are implicated in opioid addiction. 
 
Keywords: Buprenorphine, opioid addiction, brain-derived neurotrophic factor (BDNF), 
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2.1 INTRODUCTION 
Buprenorphine (BUP) is a semisynthetic opioid used for the treatment of opioid addiction and 
moderate to severe pain, 1with doses in the range of 4-32 mg/day being required to treat opioid 
addiction in most patients.2 Due to its lower risk of toxicity at higher doses, lower abuse 
potential, accessibility for office-based treatment and limited physical dependence, BUP is 
preferred over methadone and naltrexone in the management of opioid addiction. 3,4 Similar to 
other opioids, upon binding to the mu-opioid receptor, decreased pain, euphoria and respiratory 
suppression are experienced, however with limited potency since the drug acts as a partial 
opioid receptor agonist. 5,6  
When BUP binds to the mu-opioid receptors (MORs) in the brain, levels of the principal 
neurotransmitters such as dopamine (DA), γ-aminobutyric acid (GABA),  serotonin (5-HT), 
glutamate (GLU) and norepinephrine (NE) are altered. 7 Neurotransmitters are chemical 
messengers that transmit signals from pre-synaptic to post-synaptic nerve cells, in addition they 
also play a role in immunoregulation. 8 They are involved in the regulation of moods, stress, 
learning and addiction. 9 Serotonin (5-HT) plays an important role in mood, sleep, appetite, 
sexual desire and neuroendocrine function. 10,11 Research shows that morphine (opiate) 
dependence and withdrawal is a result of serotonin neurotransmission. 12,13 Chronic 
administration of morphine increases the expression of the 5-HT2C receptor protein, which 
suppresses the expression of nicotine-induced behaviour and depression-like behaviour during 
nicotine withdrawal. 14,15  
DA has also been showed to play an important role in drug addiction 16, DA is associated with 
emotion, food intake, locomotor activity, positive reinforcement, learning and memory. 17,18 
GABA on the other hand acts as the principal mediator of synaptic inhibition. 19 When opiates 
activate MORs in the ventral tegmental area (VTA), GABA interneurons are inhibited, 
ultimately increasing the release of DA in its projecting regions viz. the nucleus accumbens 
(NAc) and prefrontal cortex (PFC). 20,21 Working in opposition to GABA, GLU is the major 
excitatory neurotransmitter in the mammalian brain, being involved in neuronal plasticity, 
learning, memory processes and plays an unquestionable role in opioid addiction. 22,23 In opioid 
reward, GLU is critical for the formation and maintenance of opioid memories that are formed 
after repeated drug use, which are simply a combination of memories regarding the opiate 
experience. 24 These opioid memories trigger cravings and relapse. Opioid withdrawal 
symptoms have been strongly associated with the locus ceruleus (LC), where NE is produced 
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and facilitates drowsiness, low blood pressure and respiratory depression. 25 In addition to 
changes in these chemical messengers, gene expression regulators such as cyclic AMP 
response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) have 
been shown to be important transcription factors in modifying NT levels in response to 
extracellular stimuli. 26 
CREB is a transcription factor that is involved in neuronal survival, memory, learning and drug 
dependence. 27,28 The phosphorylation of CREB leads to its activation and enables it’s  binding 
to cAMP response element (CRE) sites which induces the expression of downstream genes. 29 
This includes genes that alter neurotransmitter levels and genes encoding transcription, signal 
transduction factors and metabolic enzymes. 30 Opiates inhibit cAMP signalling pathways 
which decreases neuronal firing of the LC, which is implicated in opioid withdrawal. 31 In the 
chronic administration of opioids, there is an upregulation of the cAMP system that leads to 
tolerance, dependence and drug-seeking behaviour. 32 In addition, an increase in 
phosphorylated CREB is noted, binding to target genes and modulating their expression. 29 
Biogenic amine neurotransmitters such as DA, 5-HT and NE have been shown to regulate 
CREB activation through G-protein receptors and G-protein mediated 2nd messenger 
signalling. 33 Evidence strongly suggests that the function and development of DA and 5-HT 
is a result of BDNF modulation.34 
BDNF is a neurotrophic peptide that facilitates neuronal cell growth, maintenance and 
plasticity, has also been shown to be involved in drug addiction. 35 Previous studies show that 
dopaminergic, serotonergic and GABAergic development and functions are modulated by 
BDNF. 36-38  Pre-synaptically, BDNF regulates GLU release via the tyrosine kinase Trk B 
receptor and extracellular calcium mobilization. 39,40 Studies that have measured serum BDNF  
levels in heroin addicts have shown contradicting results. 36  Zang et al. and Angelucci et al. 
found BDNF serum levels lower than the control group (p < 0.01 and p < 0.05, respectively), 
whereas Zhang et al. found the opposite with serum BDNF levels of heroin addicts to be higher 
than in controls (p = 0.001). 38,41,42 In addition, a study where opiate dependent individuals 
were treated with heroin showed a significant increase in BDNF serum levels (p = 0.009) in 
these patients. 43 The evidence strongly implicates neurotransmitters and, CREB and BDNF, 
in the pathophysiology of opiate addiction, however there is a lack of information regarding 
how BUP alters these pathways in the management of opioid addiction. Therefore, we aim to 
investigate the functional (neurotransmitter) and molecular (CREB/BDNF expression) 
pharmacodynamic changes associated with BUP administration in a rodent model. 
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2.2 MATERIALS AND METHODS 
2.2.1 Experimental Animal Model 
The animal experiments conducted in this study were approved by the Institutional Animal 
Research Ethics Committee, University of KwaZulu-Natal (approval reference: 
AREC/013/019M). Male Sprague-Dawley rats (150-200 g) were obtained from the Biomedical 
Resource Unit (BRU) of the University of KwaZulu-Natal (Durban, South Africa). Prior to the 
experiment, rodents were allowed to acclimatize for a period of one week. Animals were 
housed in clear polycarbonate cages, with a 12-h light/dark cycle at 21-24 ˚C, with 
environmental enrichment in the form of shredded paper and allowed ad libitum access to water 
and standard rodent feed.  
The intranasal administration route is an effective route for rapid brain drug delivery and as a 
result has received attention for emergency administration in overdose situations, in addition 
this route is novel in the administration of BUP in rodent brain.44,45 The rats (n = 3) were first 
anesthetized with isoflurane to minimize discomfort during intranasal administration and to 
prevent any unwanted movements during drug dosing. A previously reported method by our 
lab was implemented, where rats were placed in a supine position with their nose at an upright 
90˚ angle to enable snorting of drops of 0.3 mg/mL of buprenorphine into the nasal cavity. A 
total of 36 μL/rat was administered using a micropipette (Eppendorf-P10), where 6 μL/nostril 
was dispensed in both naris with a hold time of 2 min between each dose. 46 
Animals were euthanized through decapitation at; 0, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h post drug 
administration. Blood was collected, the brain surgically extracted, quickly frozen using liquid 
nitrogen vapor and stored at -80 ˚C until time of LC-MS analysis. Tissue samples for gene 
expression studies and protein analysis were stored at -80 ˚C in Qiazol and cytobuster until 
time for analysis. 
2.2.2 Chemicals and Reagents 
LC-MS grade Acetonitrile and Methanol were purchased from Merck Ltd (Darmastadt, 
Germany) and Honeywell (Steinham, Germany), respectively. Ultrapure water was purified 
using a Milli-Q® water purifying system (Merck Millipore, Burlington, MA). All 
neurotransmitter standards; Dopamine hydrochloride, γ-Aminobutyric acid, L-Glutamic acid 
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monosodium salt monohydrate, Norepinephrine and Serotonin were supplied by Sigma Aldrich 
(St. Louis, USA). The deuterated internal standard was obtained from Clearsynth® (Ontario, 
Canada). IsoFor (Isoflurane) was obtained from Safeline Pharmaceuticals (Durban, South 
Africa) and BUP from Pharmed Pharmaceuticals (Durban, South Africa). 
2.2.3 Sample Preparation for LC-MS 
Brain tissue samples were homogenised in one volume of ultrapure water (1 mL/g) using a 
tissue homogenizer from OMNI International-The Homogenizer Company® (Kennesaw 
Georgia, USA). 850 µL of methanol was added to 100 µL aliquot of brain homogenate and 50 
µL of internal standard, followed by vortexing for a minute. The mixture was centrifuged at 
4˚C, at 4500 × g for 10 min for protein precipitation. A modified solid phase extraction was 
performed using a Discovery® DSC-18 (100 mg) cartridge (Merck, South Africa) to filter the 
resultant supernatant. The flow from the SPE was collected and transferred to LC-MS vials and 
dried using a ZipVap nitrogen evaporator (Gauteng, South Africa). The drying temperature 
was set to 55˚C for 15-20 min, with continuous nitrogen flow until dryness was achieved. The 
samples were resuspended in 200 µL of ultrapure water and ready for LC-MS analysis. 
2.2.4 Liquid Chromatography - Mass Spectrometry 
The LC-MS system consisted of a Thermo Scientific Vanquish Ultra-High-Performance Liquid 
Chromatography (UHPLC) (Waltham, MA USA) system coupled to TSQ Quantis Triple Quad 
mass spectrometer (Waltham, USA). The mass spectrometer was equipped with a heated 
electrospray ionization (H-ESI) source that was set to operate in the positive ionisation mode 
with a source spray voltage of 4809 V. Separation was achieved using a Poroshell 120 EC-C18 
column (50 × 4.6 mm and 2.7 µm particle size) (Agilent Technologies, USA) which was 
maintained in a controlled column compartment with a temperature of 25˚C. The mobile phases 
used were; A: LC-MS grade water with 0.1% (v/v) formic acid and B: methanol with 0.1% 
(v/v) formic acid with a sample injection volume of 10 µL and a flow rate of 0.8 mL/min flow 
rate. The elution gradient consisted of an equilibration time of 1 min with 15% B, 0 min: 15% 
B, 1 min: 70% B, 1.1 – 5.5 min: 95% B, 5.1 – 5.6: min 15% with a total run time of 8 min. The 
mass spectrometer parameters used for mass isolation and ion quantification are shown in the 
Supplementary Information (SI-Table 1).  
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2.2.5 Total RNA isolation  
Briefly, 100 µL of brain sample was added to 500 µL of Qiazol reagent (Qiagen, Hilden, 
Germany) and stored at -80˚C overnight for isolation of RNA. The samples were thawed at 
room temperature (RT) and a 100 µL of chloroform was added, centrifuged for 15 min at 
12 000 × g at 4˚C. 250 uL of aqueous phase was transferred to a fresh 1.5 mL micro-centrifuge 
tube. Working on ice, 250 µL of isopropanol was transferred to the tube and sample incubated 
overnight at -80˚C. Samples were centrifuged for 20 min at 12 000 × g at 4˚C, the supernatant 
removed and the pellet washed with 500 µL of 75% cold ethanol. The sample was then 
centrifuged for 15 min at 7 400 × g at 4˚C, RNA pellets air dried for 30 min at RT and ethanol 
discarded. The RNA pellets were resuspended in 15 µL of nuclease-free water and incubated 
at RT for 3 min, before quantification of RNA. Total RNA was quantified and purified using 
NanodropTM 2000 spectrophotometer (Thermo-Fisher Scientific, SA). RNA purity was 
evaluated using the A260/A280 absorbance ratios. All samples were standardised to a final 
concentration of 1000 ng/µL.  
2.2.6 CREB and BDNF mRNA expression 
Reverse transcription of total RNA (1000 ng/µL) into cDNA was done using the Maxima H 
Minus First Strand cDNA Synthesis Kit (Thermo-Fisher Scientific, California, USA) as per 
manufacturer’s instructions. PowerUpTM SYBRTM Green Master Mix (Thermo-Fisher 
Scientific, California, USA) was used to determine CREB and BDNF mRNA expression 
according to manufacturer’s protocol. [BDNF: Sense: 5'-
GAATTCATGACCATCCTTTTCCTTACTATG-3'; CREB: Sense: 5'-
CCAAACTAGCAGTGGGCAGTATATT-3'] (1 uL), anti-sense primer (25 µM) [BDNF: 
Anti-sense 5'-AAGCTTTCTTCCCCTTTTAATGGTCAG-3'; CREB: Anti-sense 5'-
GGTACCATTGTTAGCCAGCTGTATT-3'] was prepared. To normalise the expression of 
CREB and BDNF the GAPDH house keeping gene was used [GAPDH: Sense 5’-
GGCACAGTCAAGGCTGAGAATG-3’, Anti-Sense 5’–
ATGGTGGTGAAGACGCCAGTA-3’]. The Applied BioSystems ViiA 7 Real-Time PCR 
system (Thermo-Fisher Scientific, California,  USA) was set to 95˚C for Initial denaturation (1 
cycle) for 8 min, followed by PCR which consisted of 40 cycles of denaturation at  95˚C for 
15 sec, annealing  at 60˚C for 40 sec and extension for 30 s at 72˚C. Data analysis was done 
using methods described by Livak and Schmittgen (2001) and represented as a fold change 
relative to control.47 
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and reached their peak concentrations of 2060.85 ± 112.52 ng/mL, 1018.46 ± 49.60 ng/mL and 
1389.94 ± 112.30 ng/mL, respectively after 8 h. 5-HT showed the lowest range of concentration 
(20.5-22.5 ng/mL) at all time points, with a peak concentration of 22.09 ± 0.190 ng/mL at 24 
h. DA tissue concentrations increased rapidly in tandem with BUP and peaked after 1 h with a 
peak concentration of 42.33 ± 2.11 ng/mL and decreased close to baseline levels at 2 h when 
BUP was at its highest concentration.  
 
 
Figure 2. 1: Mean brain concentration at different time intervals of (a) BUP ;  (b) 5-HT; 
(c) DA; (d) GLUT; (e): GABA; (f) NE following intranasal administration of a single dose 
of 0.3 mg/mL BUP in male Sprague-Dawley rats (n = 3). Values are expressed as mean ± 
SD. (*p<0.0332, **p<0.021 ***p<0.0002 ****p<0.0001). 
 
2.3.2 Effect of Buprenorphine on CREB and BDNF expression 
CREB and BDNF gene expression was measured using qPCR in the brain tissue of rodents 
sacrificed at different time points post a 0.3 mg/mL intranasal administration of BUP. CREB 
gene expression varied when compared to control, there was a significant downregulation at 1 
and 6 h post dosing (****p<0.0001 and *p<0.0332 respectively). However, at 2 and 8 h the gene 
was significantly upregulated (****p<0.0001 and *p<0.0332 respectively) (Figure 2.2). BDNF 
expression was significantly upregulated (p<0.0159) with a maximum of 66.06-fold relative to 
control at 8 h post drug administration. (Figure 2.3).  
 




Figure 2. 2: CREB gene expression in half of male Sprague-Dawley rat brain at different 
time intervals following 0.3 mg/mL single dose of BUP. Data is represented as mean ± SD 
(n = 3). (*p<0.0332, **p<0.021 ***p<0.0002 ****p<0.0001). 
 
 
Figure 2. 3: BDNF gene expression in half of male Sprague-Dawley rat brain at different 
time intervals following 0.3 mg/mL single dose of BUP. Data is represented as mean ± SD 
(n = 3). (*p<0.0332, **p<0.021 ***p<0.0002 ****p<0.0001). 
 
 




In this study, we investigated the pharmacodynamic effects of intranasally administered BUP 
(0.3mg/ml) on NT levels and BDNF and CREB expression in the rodent brain at 0, 0.25, 0.5, 
1, 2, 4, 6, 8 and 24 h post drug administration. Mean tissue concentration-time profiles of BUP 
and NTs are shown in Figure 2.1a-f. The pharmacokinetic parameters of BUP are also 
summarized in Table 2.1. The results show that BUP entered the brain soon after administration 
and was detectable as early as 0.25 h post dosing, reaching a maximum tissue concentration 
(Cmax) of 1.21 ± 0.0523 ng/mL after 2 h (Tmax). There is a lack of literature information 
regarding the pK of BUP in the human or rodent brain as studies focus on plasma drug levels, 
however a study by Kendall et al. (2014) also obtained a Tmax of 2 h in the brain after 
subcutaneously administering 0.3 mg/mL of BUP-HCl in a murine model.48 While Gopal et al. 
(2002) were unable to completely characterise the pK profile of BUP following a 0.1 and 0.3 
mg/mL dose which was intravenously administered to rats, due to very low tissue drug 
concentrations.49 An 8 mg intranasal and sublingual administration of BUP in humans showed 
plasma Cmax of 11.2 and 2.19 ng/mL, respectively with a Tmax of 34.5 min and 0.67 h, 
respectively.50,51  
All NTs (GABA, GLUT, NE, 5-HT and DA) in this study were altered by BUP administration 
when compared to the controls at various time points post drug administration (Figure 2.1). 
GABA levels steadily increased and reached a peak concentration of 2060.85 ± 112.51 ng/mL 
at 8 h post dose, then gradually decreasing to 24 h. GLUT and NE also reached peak 
concentrations at 8 hours post dose, however with lower concentrations of 1018.46 ± 49.60 and 
1389 ± 118. 30 ng/mL respectively (Figure 2.1).  GABA and DA were the most significantly 
affected by the administration of BUP with GABA levels being significantly increased and DA 
being significantly decreased throughout the duration of the treatment. Both of these NTs are 
known to play a critical role in the VTA, an area strongly associated with  opioid addiction, 
where GABA interneurons are inhibited and cause and increase of DA in NAc and PFC.21 The 
increase of GABA and decrease of DA, suggests that BUP is able to antagonize the 
neurotransmitter changes seen in opioid addiction. Decreases in DA reduces the risk of 
addiction while increases in GABA reduces the stimulation associated with drug use. The 
initial increase in DA is similar to the findings of Marquez et al. (2007) who showed increased 
locomotor activity in mice which received an acute dose of BUP (3 mg/kg, sc), since DA 
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regulates locomotor activity this may account for the initial increase observed in our study.18,52 
It is proven that opioid drugs supress NE, which results in respiratory depression, drowsiness 
and low blood pressure.25 This study shows  that BUP alters NE concentration in the brain by 
causing a gradual significant increase, which peaks at 8 h with a concentration of 1389 ± 112.30 
ng/mL (p<0.021), this again suggests BUP’s efficacy in opposing the neurotransmitter changes 
associated in opioid addiction and its potential to combat opioid induced respiratory depression. 
5-HT was not significantly altered post BUP administration, however its concentration did 
show an upward trend. These findings suggest that the mechanism of action of BUP does not 
involve the modulation of 5-HT in the brain. The results may indicate that intranasal 
administration of BUP provides direct drug delivery to the central nervous system, possibly via 
the trigeminal nerve and olfactory tubes.53 This is suggested by the rapid changes in 
neurotransmitter levels, as early as 1-2 h post drug administration. 
Intranasal administration of a 0.3 mg/mL dose of BUP lead to significant upregulation of BDNF 
in the rodent brain at 8 h post drug administration. This is beneficial in opioid addiction since 
a study has shown that chronic morphine exposure increases the inhibition of the RNA 
polymerase Ⅱ enzyme at the BDNF promotor region, thereby preventing RNA synthesis 
leading to  decreased BDNF gene expression.54 Porcher et al. also found that GABAergic 
development is modulated by BDNF,37 this relationship was confirmed in our study since both 
GABA concentration (Figure 2.1) and BDNF  expression (Figure 2.2) peaked at 8 h following 
drug dosing.  CREB is known to regulate the expression of BDNF, which could account that 
decreased CREB levels reduce BDNF levels.55 Our results show that CREB gene expression 
varied throughout the treatment period, being significantly upregulated at 2 h (****p<0.0001) 
and 8 h (*p<0.0332) and downregulated at 1 h (****p<0.0001) and 6 h (*p<0.0332).56 With 
CREB levels reaching its maximum expression at 8 hours when BDNF expression was at its 
peak. 
The results obtained from this study showed that BUP does significantly influence NTs 
(GABA, GLUT, NE, 5-HT and DA) and the gene expression of BDNF and CREB. Based on 
previous findings in literature, these changes are in direct opposition to those seen in models 
of opioid addiction. Therefore, this study greatly contributes to the understanding of the 
pharmacodynamic effects of BUP in the treatment and management of opioid addiction. 
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3.1 General conclusion and future recommendations 
Buprenorphine (BUP) is a semisynthetic opioid derivative used to treat opioid addiction and 
pain, by acting as a partial agonist at the mu-opioid receptor and as an antagonist at delta- and 
kappa-opioid receptors contributing to its unique pharmacodynamic effects. In addition, BUP 
has a high opioid receptor affinity and slow dissociation rate from receptors resulting in a 
prolonged duration of action.1 However, the exact mechanism by which BUP treats opioid 
addiction is unknown. This drug, like other opioids, is believed to have an effect on 
neurotransmitters, BDNF and CREB. The primary neurotransmitters believed to be altered by 
BUP include DA, GABA, GLU, NE and 5-HT.  The mesocorticolimbic dopamine system is a 
neurotransmitter system that contributes significantly to opioid addiction. It originates from the 
VTA and involves indirect dopamine firing to the PFC and NAc, which is mediated via the 
inhibition of GABA neurons.2 Opioid reward also requires glutamatergic neurotransmission, 
which involves GLUT, a major excitatory NT that is required for mu-opioid receptor 
activation.3 During opioid withdrawal, NE is also supressed which results in drowsiness, low 
blood pressure and respiratory depression.4 5-HT which plays an important role in appetite, 
mood, memory, sexual behaviour and neuroendocrine function has also been shown to 
participate in the development of opioid dependence and withdrawal of the opioids. Chronic 
treatment of morphine has demonstrated an increase in the expression of 5-HT2C receptor 
protein in NAc, VTA and LC.5 Opioids also affect neurobiological transcription factors BDNF 
and CREB.6,7 BDNF plays a crucial role in the modulation of neural and behavioural plasticity 
in drug abuse.8 The transcription factor, CREB, facilitates in learning and memory, circadian 
rhythm, depression and addiction.9  The present study, therefore, evaluated the effect of 
intranasal BUP on the neurotransmitters (GABA, GLUT, NE, 5-HT and DA) and the 
expression of CREB and BDNF. 
In this study, 27 male Sprague-Dawley rats (150 – 200 g) were intranasally administered 0.3 
mg/mL of BUP and euthanised at: 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h post drug dosing. Thereafter, 
brain samples were collected and homogenised for analysis. The pharmacokinetics of BUP and 
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neurotransmitter (GABA, GLUT, NE, 5-HT and DA) levels were determined using LC-MS 
and gene expression of CREB and BDNF was quantified using qPCR.  
The pharmacokinetic parameter of BUP show that a Cmax of 1.21 ± 0.0523 ng/mL was achieved 
at a Tmax of 2 h in the healthy rodent brain. The AUC0-inf was 25.04 ng × h/mL and the half-life 
(T1/2) 6.27 h. These pharmacokinetic results were consistent with that of Kendall et al. who 
found a Tmax of 2 h and Cmax of 19.1 ng/mL, where they also administered 0.3 mg/mL of BUP-
HCl in a murine model.10 Post BUP dosing, the concentration of 5-HT decreases at 0.25 h and 
increases steadily reaching its peak concentration (22.09 ± 0.190 ng/mL) at 24 h. DA rapidly 
increases soon after BUP administration and concentration peaks at 42.33 ±2.11 ng/mL after 
an hour. However, its concentration is very low when compared to GABA which is initially 
above 1000 ng/mL and peaks at 8 h reaching a concentration of 2060.35 ng/mL. Literature 
states that the binding of opioids to mu-opioid receptors on GABA neurons, leads to the 
inhibition of these neurons and an indirect firing of DA neurons is achieved.11 GLUT and NE 
also reached their maximum concentrations after 8 h, with their Cmax being  1018.46 ± 49.60 
ng/mL and 1389.94 ± 112.30 ng/mL, respectively. Gene expression results showed an overall 
significant upregulation (*p<0.0159) in BDNF expression in the brain tissue in response to 
BUP administration. However, CREB expression varied showing significant upregulation (2 
and 8 h, by ****p<0.0001 and *p<0.0332 respectively) and downregulation (1 and 6 h, by 
****p<0.0001 and *p<0.0332 respectively). Overall, these results give an indication of the 
pharmacodynamic effects of BUP in the healthy brain. 
This study demonstrated that BUP does significantly influence the levels of NTs (GABA, 
GLUT, NE, 5-HT and DA) and the gene expression of CREB and BDNF. An important finding 
in this study showed decreased levels of DA and higher levels of GABA with BUP 
administration. These pharmacodynamic effects are beneficial in treating opioid addiction 
since it is associated with higher levels of DA and lower levels of GABA. 12 In the future, we 
propose treating rats with different doses of BUP to clearly demonstrate the effect of the drug 
on the NTs (GABA, GLUT, NE, 5-HT and DA) and the gene expression of CREB and BDNF. 
In addition, treat the rats with BUP for longer periods with chronic doses to determine the long-
term effects and addictive potential of BUP. Thereafter, studying neurobehavioral function, 
social interaction and locomotor activity by performing the novel object recognition test and 
social interaction tests to determine if there is any cognitive decline and social aversion due to 
BUP administration. Moreover, the analysis of other genes , such as the nerve growth factor 
(NGF) gene which belong to the same family of neurotrophins as BDNF and has been 
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previously studied together after methadone or BUP treatment in rats and have been shown to 
play a role in addiction and its treatment.13,14 This will ultimately lead to a deeper understanding 
of the mechanisms of BUP’s action and how they can be exploited by psychiatrists to better 
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Appendix I - Supplementary information 
Functional and molecular changes associated with intranasal buprenorphine 
administration in a healthy rodent model 
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1. Calibration sample preparation 
In order to prepare calibration standards, 1 mg of each neurotransmitter standard was weighed 
and dissolved in 100 uL of water and 900 uL of methanol to produce a neurotransmitter 
multimix with a final concentration of 1mg/mL of each neurotransmitter. The multimix was 
then diluted with MeOH to 10 ug/mL and 1 ug/mL working solutions. An internal standard 
multimix was also prepared following the same procedure and diluted with MeOH to a 10 
ug/mL working solution. Different concentrations of 50, 100, 250, 500, 750, 1000 ng/mL were 
prepared for the calibration curve. The Internal standard volume remaining constant 
throughout, 75 uL. Buprenorphine calibration samples were prepared as follows: 0.39, 0.78, 
1.00, 1.56, 3.13, 5.00, 6.25, 10.00 ng/mL using methanol. 
 
Table S 1: Mass spectrometer selected reaction monitoring and ion optics parameters 
used for the analysis of buprenorphine and neurotransmitters  

























137 Quantifier 14.55 78 9.473 
90.946 Qualifier 27.51 78 9.473 




87 Quantifier 13.41 30 9.473 
46 Qualifier 55 30 9.473 
85.875 Qualifier 55 30 9.473 
Glutamate Positive 148.05 
84.071 Quantifier 18.98 30 9.473 





152.054 Quantifier 10.23 79 9.473 
107.018 Qualifier 23.99 79 9.473 





159.982 Quantifier 10.23 30 9.473 
114.929 Qualifier 46.7 30 9.473 





164.02 Quantifier 10.23 192 9.473 
78.557 Qualifier 34.57 192 9.473 
118.042 Qualifier 26.49 192 9.473 
Buprenorphine Positive 468.3 55.125 Quantifier 47.23 114 9.473 
   396.3 Qualifier 35 114 9.473 








Figure S 1: Showing the precursor ion mass spectra of buprenorphine [M+H]+ at 468.31 
m/z embedded with its liquid chromatogram at 2.61 min as separated on a Poroshell 120 





Figure S 2: Showing the precursor ion mass spectra of serotonin [M+H]+ at 177.00 m/z 
embedded with its liquid chromatogram at 1.17 min as separated on a Poroshell 120 EC-
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Figure S 3: Showing the precursor ion mass spectra of D4-serotonin [M+H]+ at 181.16 
m/z embedded with its liquid chromatogram at 1.13 min as separated on a Poroshell 120 




Figure S 4: Showing the precursor ion mass spectra of dopamine [M+H]+ at 154.08 m/z 
embedded with its liquid chromatogram at 0.78 min as separated on a Poroshell 120 EC-
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Figure S 5: Showing the precursor ion mass spectra of GABA [M+H]+ at 104.35 m/z 
embedded with its liquid chromatogram at 0.64 min as separated on a Poroshell 120 EC-




Figure S 6: Showing ion mass spectra of glutamate [M+H]+ at 148.05 m/z embedded with 
its liquid chromatogram at 0.65 min as separated on a Poroshell 120 EC-C18 column (50 
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Figure S 7: Showing ion mass spectra of norepinephrine [M+H]+ at 170.09 m/z embedded 
with its liquid chromatogram at 0.64 min as separated on a Poroshell 120 EC-C18 column 
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Table S 2: Concentration of BUP and NT’s, with BDNF and CREB fold changes at 
different time points. 
Time 
(h) 
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DA 41,984 
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667,3207 
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